We analyzed the epidemiological profile of women who inserted copper intrauterine device (Cu-IUD), subdermal etonogestrel implant (ENG), tubal ligation (TL), depot medroxyprogesterone acetate (DMPA) or did not choose a contraceptive method (NCM) in the immediate postpartum. Also, we compared the contraceptive effectiveness of Cu-IUD and DPMA with non-MAC. Data from 20896 women were collected, of which 8183 (39%) opted for Cu-IUD, 559 (2.5%) DPMA, and 10989 (52.5%) for any method. When comparing these groups, women in the DPMA were younger (26.5+=7.3, p<0.05), and NCM showed women with a lower number of pregnancies (2.2+-1.3, p<0.05). Subjects in the TL group (4,6%) had the higher number of pregnancies (3,8+-1.2, p<0.05), and ENG group, the highest number of miscarriages (1.6+-1.3, p<0.05). Of those women who returned pregnant, 5.5% belonged to the DPMA group, 6% to the NCM group, and 2.3% to the Cu-IUD. Women who opted for Cu-IUD insertion were younger, had more pregnancies and vaginal delivery when compared to those who did not choose a method. Of those women who returned, the minority opted for Cu-IUD compared to those that opted for DPMA or no method.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Comite de Etica em Pesquisa da Faculdade de Medicina do ABC gave ethical approval for this work. ID - CAAE: 48612021.3.0000.0082

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced in the present work are contained in the manuscript